Objectives <p>To compare ethanol pharmacokinetics before and after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) over a three-year period.</p> Methods <p>This was a prospective, longitudinal, non-randomized controlled study at St. Olavs Hospital, Trondheim, including 33 adults without histories of alcohol use disorder (RYGB: <i>n</i> = 14; SG: <i>n</i> = 19). Participants underwent oral and intravenous ethanol challenge tests preoperatively and at 3, 12, and 36 months postoperatively. Primary outcomes included maximum plasma concentration (C<sub>max</sub>), time to reach maximum concentration (T<sub>max</sub>), and area under the curve to the last measurable concentration (AUC<sub>last</sub>).</p> Results <p>The ethanol uptake after both surgical procedures was bioequivalent for AUC<sub>last</sub>, but not for C<sub>max</sub> and T<sub>max</sub>. At 12 months, RYGB gave a 27% higher C<sub>max</sub> and 31% shorter T<sub>max</sub> than SG, while no significant differences were observed for AUC<sub>last</sub>. Both procedures induced profound and persistent alterations in ethanol pharmacokinetics over the three-year period: C<sub>max</sub> and AUC<sub>last</sub> approximately doubled, and T<sub>max</sub> was reduced to about half the preoperative value. C<sub>max</sub> occurred within 9–15 min compared to 25–29 min before surgery. Patients also had concomitant reductions in total body water, averaging 3.2 kg after SG and 4.8 kg after RYGB at 12 months.</p> Conclusion <p>Both RYGB and SG permanently altered ethanol pharmacokinetics, resulting in faster absorption, higher peak concentrations, and higher systemic exposure of alcohol. These changes, which were more pronounced after RYGB, may increase the risk of alcohol use disorders post-surgery. Awareness of the pharmacokinetic effects on RYGB and SG may be relevant for patient education, surgical decision-making, and postoperative monitoring.</p> Clinical trial registration <p>This study was registered in ClinicalTrials.gov on May 15 2013. Identifier: NCT01840020.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Ethanol pharmacokinetics before and after sleeve gastrectomy and Roux-en-Y gastric bypass: a 3 year prospective study (the BAR-TRIAL)

  • Magnus Strømmen,
  • Ola Dale,
  • Christian Klöckner,
  • Ida Tylleskär

摘要

Objectives

To compare ethanol pharmacokinetics before and after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) over a three-year period.

Methods

This was a prospective, longitudinal, non-randomized controlled study at St. Olavs Hospital, Trondheim, including 33 adults without histories of alcohol use disorder (RYGB: n = 14; SG: n = 19). Participants underwent oral and intravenous ethanol challenge tests preoperatively and at 3, 12, and 36 months postoperatively. Primary outcomes included maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), and area under the curve to the last measurable concentration (AUClast).

Results

The ethanol uptake after both surgical procedures was bioequivalent for AUClast, but not for Cmax and Tmax. At 12 months, RYGB gave a 27% higher Cmax and 31% shorter Tmax than SG, while no significant differences were observed for AUClast. Both procedures induced profound and persistent alterations in ethanol pharmacokinetics over the three-year period: Cmax and AUClast approximately doubled, and Tmax was reduced to about half the preoperative value. Cmax occurred within 9–15 min compared to 25–29 min before surgery. Patients also had concomitant reductions in total body water, averaging 3.2 kg after SG and 4.8 kg after RYGB at 12 months.

Conclusion

Both RYGB and SG permanently altered ethanol pharmacokinetics, resulting in faster absorption, higher peak concentrations, and higher systemic exposure of alcohol. These changes, which were more pronounced after RYGB, may increase the risk of alcohol use disorders post-surgery. Awareness of the pharmacokinetic effects on RYGB and SG may be relevant for patient education, surgical decision-making, and postoperative monitoring.

Clinical trial registration

This study was registered in ClinicalTrials.gov on May 15 2013. Identifier: NCT01840020.